The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype
Open accessAbstract
Background: The disease course and long‐term outcome of patients with organic acidurias (OAD) and urea cycle disorders (UCD) are incompletely understood. Aims: To evaluate the complex clinical phenotype of OAD and UCD patients at different ages. Results: Acquired microcephaly and movement disorders were common in OAD and UCD highlighting that the brain is the major organ involved in these diseases. Cardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QT c interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency. Chronic renal failure was often found in MMA, with highest frequency in mut 0 patients. Unexpectedly, chronic renal failure was also observed in adolescent and adult patients with GA1 and ASL deficiency. It had a similar frequency in patients with or without a movement disorder suggesting different pathophysiology. Thirteen patients (classic OAD: 3, UCD: 10) died during the study interval, ten of them during the initial metabolic crisis in the newborn period. Male patients with late‐onset ornithine transcarbamylase deficiency were presumably overrepresented in the study population. Conclusions: Neurologic impairment is common in OAD and UCD, whereas the involvement of other organs (heart, liver, kidneys, eyes) follows a disease‐specific pattern. The identification of unexpected chronic renal failure in GA1 and ASL deficiency emphasizes the importance of a systematic follow‐up in patients with rare diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oligodendrocytes and Ischemic Brain Injury
Dewar, D., Underhill, S. M., & Goldberg, M. P. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000053472.41007.f9 · Cited by 335 · cited 1×
“…autoregulation, activation of excitotoxic pathways and entrapment of key metabolites synergize with a physiologically high cerebral energy demand (Sokoloff 1960), a lipid-rich environment that is highly susceptible to reactive oxygen species (Dewar et al 2003), and highly vulnerable cell species.”
BackgroundRequirement of argininosuccinate lyase for systemic nitric oxide production
Erez, A., Nagamani, S. C. S., Shchelochkov, O. A., Premkumar, M. H., Campeau, P. M., Chen, Y., Garg, H. K., Li, L., Mian, A., Bertin, T. K., et al. (2011) · Nature Medicine · doi:10.1038/nm.2544 · Cited by 233 · cited 2×
“Their clinical relevance is still unclear (Harting et al 2009; Garbade et al 2014), but recently reported subependymal mass lesions in adult-onset GA1 necessitate a re-evaluation of these changes (Herskovitz et al 2013).”
BackgroundSelf-citation
Cited by
Forny, P., Hörster, F., Ballhausen, D., Chakrapani, A., Chapman, K. A., Dionisi‐Vici, C., Dixon, M., Grünert, S. C., Grunewald, S., Haliloglu, G., et al. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12370 · Cited by 287
Self-citationMarras, C., Lang, A., van de Warrenburg, B. P., Sue, C. M., Tabrizi, S. J., Bertram, L., Mercimek‐Mahmutoglu, S., Ebrahimi‐Fakhari, D., Warner, T. T., Durr, A., et al. (2016) · Movement Disorders · doi:10.1002/mds.26527 · Cited by 285
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
“Even well-managed patients remain at risk for complications associated with MMA, especially intermittent metabolic decompensation and the obligate risk of disease-associated sequelae (de Baulny et al., 2005; Dionisi-Vici et al., 2006; Hörster et al., 2007; Kölker et al., 2015).”
Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia
An, D., Frassetto, A., Jacquinet, E., Eybye, M., Milano, J., DeAntonis, C., Nguyen, V., Laureano, R., Milton, J., Sabnis, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.003 · Cited by 87
“This is consistent with published reports from the European registry and network for intoxication type metabolic diseases, in which a small fraction (b20%) of MMA patients had abnormal liver function tests [38].”
ResultIlyinskii, P. O., Michaud, A. M., Rizzo, G. L., Roy, C. J., Leung, S. S., Elkins, S. L., Capela, T., Chowdhury, A., Li, L., Chandler, R. J., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.015 · Cited by 39
Metadata
- Authors
- Kölker, S., Valayannopoulos, V., Burlina, A. B., Sykut‐Cegielska, J., Wijburg, F. A., Teles, E. L., Zeman, J., Dionisi‐Vici, C., Barić, I., Karall, D., Arnoux, J., Avram, P., Baumgartner, M. R., Blasco‐Alonso, J., Boy, S. P. N., Rasmussen, M. B., Burgard, P., Chabrol, B., Chakrapani, A., Chapman, K., Cortès i Saladelafont, E., Couce, M. L., de Meirleir, L., Dobbelaere, D., Furlan, F., Gleich, F., González, M. J., Gradowska, W., Grünewald, S., Honzik, T., Hörster, F., Ioannou, H., Jalan, A., Häberle, J., Haege, G., Langereis, E., de Lonlay, P., Martinelli, D., Matsumoto, S., Mühlhausen, C., Murphy, E., de Baulny, H. O., Ortez, C., Pedrón, C. C., Pintos‐Morell, G., Pena‐Quintana, L., Ramadža, D. P., Rodrigues, E., Scholl‐Bürgi, S., Sokal, E., Summar, M. L., Thompson, N., Vara, R., Pinera, I. V., Walter, J. H., Williams, M., Lund, A. M., & Garcia Cazorla, A.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2015-04-15
- Volume
- 38
- Issue
- 6
- Pages
- 1059-1074
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W1990508860
- Cited by
- 236
- References
- 2
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.